BioArctic: Lecanemab receives priority review status in Japan ...Middle East

STOCKHOLM, Jan. 30, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the application for manufacturing and marketing approval for lecanemab (generic name, U.S. brand name: LEQEMBI™) in Japan has been designated for Priority Review by...

Read More Details
Finally We wish PressBee provided you with enough information of ( BioArctic: Lecanemab receives priority review status in Japan )

Also on site :

• Term Sheet Next: How Facebook’s former chief revenue officer is coaching the next generation of startup founders
• At least 7 dead after wave of explosions hit southwest Colombia, authorities say
• Popular Dunkin’ Menu Item Gets a ‘Glow-Up’ in Limited-Edition Release